Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Introduction or Objective</h3><p>Men with favorable‐risk prostate cancer (PCa) on active surveillance may benefit from intervention strategies to slow or prevent disease progression and the need for definitive treatment. Pomegranate and its extracts have shown antiproliferative and proapoptotic effects in cell lines and animal models, but its effect on human prostate cancer as a target tissue remain unclear. Objectives of this trial include pomegranate's ability to alter serum and prostate tissue biomarkers and the ability of an active surveillance cohort to adhere to a chemoprevention trial for 1 year.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Men with organ‐confined, favorable‐risk PCa on AS were randomly assigned to receive pomegranate fruit extract (PFE) 1000 mg (<i>n</i> = 15) or placebo (<i>n</i> = 15) once daily for twelve months. Prostate biopsies were performed at study entry and upon completion of the 1‐year intervention. Plasma and urinary biomarkers were analyzed utilizing immunoassays and HPLC. Tissue proteins were assessed by immunohistochemistry (IHC) and measured by automated quantitation. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>PFE was well‐tolerated with no significant toxicities. One patient withdrew before study initiation and 29 completed the 1‐year intervention. No differences in plasma insulin‐like growth factor‐1 (IGF‐1) levels, prostate‐specific antigen doubling time, or biopsy kinetics were observed. Metabolites including urolithin A and urolithin A‐gluc were detected more frequently in the PFE arm in both urine and plasma (<i>p</i> < .001 and <i>p</i> = .006, respectively). IHC analyses revealed reductions from baseline in 8‐OHdG (a DNA damage marker) (<i>p</i> = .01) and androgen receptor expression (<i>p</i> = .04) in prostate tumor associated with PFE treatment. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>PFE administration for 12‐month was well‐tolerated and the protocol followed in an active surveillance population. Analyses suggest that PFE contains bioactive compounds capable of altering biomarkers involving oxidative stress and androgen signaling in prostate tumor and normal‐appearing adjacent tissue. No alterations in the IGF axis were noted. This finding of study adherence and target activity provides a rationale for the further investigation of PFE in the active surveillance population.</p></section>

Safety of purified isoflavones in men with clinically localized prostate cancer.

Soy and Isoflavone Intake Associated with Reduced Risk of Ovarian Cancer in Southern Chinese Women

Isoflavones and Prostate Cancer: A Review of Some Critical Issues

A phase II randomized placebo‐controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance

Isoliquiritigenin, A Natural Anti-Oxidant, Selectively Inhibits the Proliferation of Prostate Cancer Cells

Current epidemiological knowledge about the role of flavonoids in prostate carcinogenesis

A randomized, double‐blind, placebo‐controlled trial to evaluate the role of curcumin in prostate cancer patients with intermittent androgen deprivation

The Use of Soy Isoflavones in the Treatment of Prostate Cancer: A Focus on the Cellular Effects

Effects on Serum Hormone Concentrations after a Dietary Phytoestrogen Intervention in Patients with Prostate Cancer: A Randomized Controlled Trial

Effects of Isoflavone-Rich NADES Extract of Pueraria lobata Roots and Astaxanthin-Rich Phaffia rhodozyma Extract on Prostate Carcinogenesis in Rats

Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer

A Novel Tomato-Soy Juice Induces A Dose-Response Increase In Urinary And Plasma Phytochemical Biomarkers In Men With Prostate Cancer

Nutritional supplement with fermented soy in men with an elevated risk of prostate cancer and negative prostate biopsies: General and oncological results from the prospective PRAECAP trial

Nutritional Supplement with Fermented Soy in Patients Under Active Surveillance for Low-Risk or Intermediate-Risk Prostate Cancer: Results from the PRAEMUNE Trial

Red clover and soy isoflavones--an in vitro safety assessment

Effects of a Phytoestrogen Intervention and Estrogen Receptor β Genotype on Prostate Cancer Proliferation and PSA Concentrations—A Randomized Controlled Trial

ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer

Relationship of serum levels and dietary intake of isoflavone, and the novel bacterium Slackia sp. strain NATTS with the risk of prostate cancer: a case-control study among Japanese men

Oral isoflavone supplementation on endometrial thickness: a meta-analysis of randomized placebo-controlled trials

A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models.

Isoflavones, substances with multi-biological and clinical properties